Skip to main content

Sjogrens

Postural Orthostatic Tachycardia Syndrome Review

Aug 07, 2023

The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.

Read Article
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway
RT @drdavidliew : Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3 LB0003 #EULAR2023
Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome? Dr. Yuz Yusof reports on abstracts OP0143 and LB0003 presented at EULAR 2023 in Milan, Italy. https://t.co/TPcdJ2rIsP https://t.co/5WZizA0TU8
Targeted therapies in Sjogren’s syndrome: are we close? There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies. https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2

Targeted therapies in Sjogren’s syndrome: are we close?

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.

 

Read Article
#Sjogrens has a positive RCT with Dazodalibep. Well tolerated in Phase 2 RCT - Congratulations -heading to phase 3 Primary outcome positive but not 2ndary but not powered for them @RheumNow #EULAR2023 @eular_org LB0003 #SSj https://t.co/Qt0KTaNjsR
#EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high symptoms burden. Phase 2 RCT of Dazodalibep (CD40L-i) showed ESSPRI improved vs PBO. Numerical improvement in other secondary (Fatigue). Will await results in Phase 3 @RheumNow https://t.co/0NzR83apeY
Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies genuinely reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3 LB0003 #EULAR2023 @RheumNow https://t.co/HYcXEzswAg
#Deeplearning in salivary biopsies in #SjogrensSyndrome - 327 pts - binary focus score (>=1) prediction the AUROC was 0.87 and for primary sjogrens diagnosis prediction it was 0.84 Quicker and cost effective in the future? @rheumnow #EULAR2023 abst#OP0232 https://t.co/Ec0zuKqpXf
Could mitochondria play a role in the pathogenesis of Sjogrens disease?! #Eular2023 https://t.co/XndW4qFf3E
Malt lymphoma in Sjogrens disease and role of PET scan. When is PET scan suggestive? Follow: Complement RF Focus score SPEP #Eular2023 https://t.co/60l8iRNvQN
#EULAR2023 #POS0120 From Sjogren to SLE. Interim analysis of Phase 2 RCT showed primary endpoint, SRI-4 + ability to sustain pred dose to ≤5 mg/d or ≤ BL from Wk16 to 28 was achieved more in Ianalumab (Bcell depletion & BAFF-R-i) vs PBO (44% vs 9%). Advance to Phase 3 @RheumNow https://t.co/Wg29uj5yqv
#EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (BAFF/APRIL-i) achieved significant reduction in ESSDAI at Wk24 vs PBO. Trend to improvement in glandular function. Intriguing option & will await Phase 3 global RCT @RheumNow https://t.co/BCiohuAfP3
#EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favoured DAZ Group. Phase 3 RCTs are underway @RheumNow https://t.co/I9uHxvRlnr
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported. https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported. https://t.co/SPmdBJ8IFh https://t.co/ad2j6XaSkK

B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's

MedPage Today
May 09, 2023

Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.

Read Article
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ https://t.co/qMGA6IdtUE
Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
×